亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery

耐受性 医学 药品 抗体-药物偶联物 治疗指标 药理学 有效载荷(计算) 连接器 癌症研究 抗体 单克隆抗体 不利影响 免疫学 计算机科学 网络数据包 操作系统 计算机网络
作者
Raffaele Colombo,Stuart D. Barnscher,Jamie R. Rich
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 1538-1538 被引量:3
标识
DOI:10.1158/1538-7445.am2023-1538
摘要

Abstract Antibody drug conjugates (ADCs) are an effective class of cancer therapeutics which have become more prominent after eight FDA approvals in the past three years. ADCs are envisioned to enable the selective delivery of a potent drug to cells that express the antibody target while sparing normal tissues, and thus to improve the therapeutic window by both increasing the maximum tolerated dose (MTD) and decreasing the minimum efficacious dose (MED) of the conjugated drug. Mounting clinical evidence does not support this simplified paradigm [1]. Herein we focus on three prominent issues in ADC development: 1. Alternative mechanisms over and above direct tumor targeting are likely to contribute to ADC therapeutic benefits in the clinic [2]. The responses to certain ADCs in patients with different levels of target antigen expression reveal some target-independent antitumor effects, suggesting the possibility that circulating payload may contribute to efficacy. 2. The preclinical optimization of ADCs is based on efficacy and tolerability in non-human animal studies. Fundamental differences in biology and translatability between species potentially overemphasize the importance of linker stability. 3. Clinical data, although limited, does not support the idea that increased ADC stability drives substantial therapeutic benefit. None of the 13 approved ADCs are completely ‘stable’ in circulation, and more stable drug-linkers have been associated with alternative toxicity profiles and no significant improvement in MTD. Novel meta-analyses and case studies assembled and integrated from >40 approved or clinically active ADCs and >70 discontinued ADCs will be presented in support of these three perspectives. The ADCs included in the analysis differ in terms of payload class, linker type, conjugation chemistry, drug-to-antibody ratio, and antibody target. Gaining a better understanding of the mechanism(s) of action of effective ADCs and the interrelationship between ADC structural components and their pharmacokinetics and pharmacodynamics is critical to inform the next generation of ADCs. References: [1] Colombo, R.; Rich, J. R., The therapeutic window of antibody drug conjugates: A dogma in need of revision. Cancer Cell 2022, 40, 1255-1263. [2] Tarcsa, E.; Guffroy, M. R.; Falahatpisheh, H.; Phipps, C.; Kalvass, J. C., Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape. Drug Discovery Today: Technologies 2020, 37, 13-22. Citation Format: Raffaele Colombo, Stuart D. Barnscher, Jamie R. Rich. Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1538.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朴实凝阳发布了新的文献求助10
3秒前
朴实凝阳完成签到,获得积分20
10秒前
激昂的谷冬完成签到,获得积分10
13秒前
动听的寒蕾完成签到,获得积分10
21秒前
平淡剑鬼完成签到,获得积分10
23秒前
小二郎的应助被执着的碧凡采纳,获得10
26秒前
执着的碧凡完成签到,获得积分20
34秒前
鲤鱼遥完成签到,获得积分10
46秒前
笑点低的天问完成签到 ,获得积分10
49秒前
机智的觅海完成签到,获得积分10
1分钟前
jyy完成签到,获得积分10
1分钟前
丘比特的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
jyy发布了新的文献求助50
1分钟前
WhiteCaramel完成签到 ,获得积分10
2分钟前
积极花瓣完成签到,获得积分10
2分钟前
自觉的孤兰完成签到,获得积分10
2分钟前
生性不爱说话完成签到,获得积分10
2分钟前
2分钟前
山是山三十三完成签到 ,获得积分0
2分钟前
Michelle完成签到 ,获得积分10
2分钟前
怕孤单的雪瑶完成签到,获得积分10
2分钟前
wubin69发布了新的文献求助10
2分钟前
凶狠的映真完成签到,获得积分10
3分钟前
小蘑菇的应助被wubin69采纳,获得10
3分钟前
Ara完成签到,获得积分10
3分钟前
耍酷的手套完成签到,获得积分10
3分钟前
JamesPei的应助被oleskarabach采纳,获得10
3分钟前
3分钟前
敏感兰完成签到,获得积分10
3分钟前
zhanghao完成签到,获得积分10
4分钟前
ZZZ完成签到,获得积分10
4分钟前
breeze完成签到,获得积分10
4分钟前
善良凝荷完成签到,获得积分10
4分钟前
4分钟前
仁爱的如天完成签到,获得积分10
4分钟前
ZZZ发布了新的文献求助10
4分钟前
NexusExplorer的应助被houhoujiang采纳,获得10
4分钟前
Taso17发布了新的文献求助20
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185149
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782677
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558763
邀请新用户注册赠送积分活动 2481208